Factsheet as on January 31, 2025
 

Factsheet as on January 31, 2025

Nippon India Pharma Fund

Back
Back
Structure
Open Ended
Fund Category
Thematic/Sectoral
Fund Manager
Sailesh Raj Bhan
Exit Load
Within 1 Month - 1%
Fund Size
Rs 8161 crs
Launch Date
June 05, 2004

Investment Objective

To generate consistent returns by investing in equity or fixed income securities of pharma and other associated companies.


Market Cap Allocation



Scheme Performance

 1 Year2 Years3 Years5 Years
Scheme (%) 15.22 31.99 18.78 25.17
Nifty 500 (%) 8.96 20.18 13.08 16.94
Returns are CAGR

Top 10 Holdings

Company Name% of Assets
Sun Pharmaceutical Industries Ltd. 14.0
Divi Laboratories Ltd. 9.2
Lupin Ltd. 8.2
Cipla Ltd. 5.6
Dr Reddys Laboratories Ltd. 5.5
Apollo Hospitals Enterprise Ltd. 5.4
Vijaya Diagnostic Centre Ltd. 3.6
Ajanta Pharmaceuticals Ltd. 3.2
Medplus Health Services Ltd. 3.2
Gland Pharma Ltd. 2.9

Year On Year Performance (Scheme V/S Nifty 500)


Ratios:
Standard Deviation    15.18
Information Ratio     0.14
Beta     0.78
Sharpe Ratio     0.22

Top 10 Sectoral Holdings (%)

SIP Returns


Source: MFI Explorer, Bloomberg.
Please refer to the disclaimer and glossaries

Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390

Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390